The bio-tech organization Dexcom Inc. (DXCM) has been experiencing a downward investment trend with its shares experiencing a dip of about 41%. The company is facing several class-action lawsuits accusing it of securities fraud and misleading investors about sales force changes and its financial outlook. Despite this, Dexcom's G7 CGM system expanded coverage for Quebec residents indicating continued product growth. Dexcom's Q2 performance saw its earnings surpass estimates, albeit with missing revenue targets. There is an ongoing discussion on whether the company stock is now a bargain, given its current low price. CGMs from DexCom were used in first-of-its-kind Polaris Dawn Mission, showing use case diversification. Moreover, Dexcom and Abbott are planning to launch the first FDA cleared OTC CGMs. Despite a challenging Q2, the company still maintains innovation with its upcoming release of Stelo.
Dexcom DXCM News Analytics from Fri, 17 May 2024 07:00:00 GMT to Sat, 05 Oct 2024 16:45:00 GMT - Rating -5 - Innovation 5 - Information 9 - Rumor 3
